Andrew Allen

Andrew Allen

Company: Gritstone bio

Job title: President, Chief Executive Officer & Co-Founder

Seminars:

Phase 1/2 Data from GRANITE (Individualized Neoantigen Immunotherapy Program) Demonstrating Objective Evidence of Efficacy in End-Stage CRC Patients who have “Cold” Tumors at Baseline 1:30 pm

• Updated results from Phase 1/2 study evaluating the safety, immunogenicity, and clinical activity of GRANITE individualized neoantigen immunotherapy • In 26 patients with end-stage solid tumors, efficacy was assessed by radiology, molecular response (ctDNA) and overall survival • GRANITE is now advancing into a potentially pivotal, randomized, controlled, phase 2/3 clinical trial (single protocol)…Read more

day: Track 1, Day 2 AM

Liquid Biopsy Applications

Chair: 10:45 am

Read more

day: Track 1, Day 2 AM

Chair’s Opening Remarks 9:20 am

Read more

day: Day 2 - Morning

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.